Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer.
biomarker
head and neck cancer (HNC)
immunotherapy
low density neutrophils (LDN)
predictive
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
21
07
2023
received:
11
04
2023
accepted:
22
09
2023
medline:
13
11
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need. This was a prospective observational study including 25 patients with HNSCC treated with immunotherapy or chemotherapy after a prior platinum-based regimen. Low density neutrophils (LDNs) and serum markers were analyzed. In the immunotherapy cohort, patients with high LDN levels had a shorter progression free survival (PFS) (1.8 months vs. 10.9 months; *p = 0.034). Also, progressors showed higher percentage of LDNs compared to non-progressors although significance was not reached (mean 20.68% vs. 4.095%, p = 0.0875). These findings were not replicated in patients treated with chemotherapy. High levels of interleukin-7 (IL7) were correlated with a significantly longer overall survival (OS) (13.47 months 3.51 vs. months, *p = 0.013). High baseline circulating LDNs and low IL7 could identify a subset of patients intrinsically refractory to ICIs as monotherapy in HNSCC.
Sections du résumé
BACKGROUND
Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need.
METHODS
This was a prospective observational study including 25 patients with HNSCC treated with immunotherapy or chemotherapy after a prior platinum-based regimen. Low density neutrophils (LDNs) and serum markers were analyzed.
RESULTS
In the immunotherapy cohort, patients with high LDN levels had a shorter progression free survival (PFS) (1.8 months vs. 10.9 months; *p = 0.034). Also, progressors showed higher percentage of LDNs compared to non-progressors although significance was not reached (mean 20.68% vs. 4.095%, p = 0.0875). These findings were not replicated in patients treated with chemotherapy. High levels of interleukin-7 (IL7) were correlated with a significantly longer overall survival (OS) (13.47 months 3.51 vs. months, *p = 0.013).
CONCLUSIONS
High baseline circulating LDNs and low IL7 could identify a subset of patients intrinsically refractory to ICIs as monotherapy in HNSCC.
Substances chimiques
Interleukin-7
0
Biomarkers
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3075-3085Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778-789. doi:10.1002/ijc.33588
Bhatia A, Burtness B. Treating head and neck cancer in the age of immunotherapy: a 2023 update. Drugs. 2023;83(3):217-248. doi:10.1007/s40265-023-01835-2
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31-46. doi:10.1158/2159-8290.CD-21-1059
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867. doi:10.1056/NEJMoa1602252
Cohen EE, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;393:156-167. doi:10.1016/S0140-6736(18)31999-8
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;394:1915-1928. doi:10.1016/S0140-6736(19)32591-7
Kargl J, Busch SE, Yang GH, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381. doi:10.1038/ncomms14381
Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30:459-489. doi:10.1146/annurev-immunol-020711-074942
Sagiv JY, Michaeli J, Assi S, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10:562-573. doi:10.1016/j.celrep.2014.12.039
Mishalian I, Granot Z, Fridlender ZG. The diversity of circulating neutrophils in cancer. Immunobiology. 2017;222:82-88. doi:10.1016/j.imbio.2016.02.001
Shaul ME, Eyal O, Guglietta S, et al. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. FASEB J. 2020;34:4204-4218. doi:10.1096/fj.201902467R
Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485-498. doi:10.1038/s41577-020-00490-y
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247. doi:10.1016/j.ejca.2008.10.026
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45-51. doi:10.1016/j.oraloncology.2018.04.008
Youn JI, Park SM, Park S, et al. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Sci Rep. 2020;10(1):9050. doi:10.1038/s41598-020-65666-x
Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63:247-257. doi:10.1007/s00262-013-1508-5
Koh J, Kim Y, Lee KY, et al. MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. Eur J Immunol. 2020;50:1810-1819. doi:10.1002/eji.202048534
Kaisar-Iluz N, Arpinati L, Shaul ME, et al. The bilateral interplay between cancer immunotherapies and neutrophils' phenotypes and sub-populations. Cell. 2022;11(5):783. doi:10.3390/cells11050783
Zuazo M, Arasanz H, Fernández-Hinojal G, et al. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Mol Med. 2019;11(7):e10293. doi:10.15252/emmm.201910293
Arasanz H, Bocanegra AI, Morilla I, et al. Circulating low density neutrophils are associated with resistance to first line anti-PD1/PDL1 immunotherapy in non-small cell lung cancer. Cancers (Basel). 2022;14(16):3846. doi:10.3390/cancers14163846
Ferrara R, Lo Russo G, Ciniselli CM, et al. 1057P baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations. Ann Oncol. 2018;33:S1038. doi:10.1016/j.annonc.2022.07.1183
Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842. doi:10.1136/jitc-2020-000842
Yamazaki N, Kiyohara J, Uhara H, et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci. 2017;108(5):1022-1031. doi:10.1111/cas.13226
Huseni MA, Wang L, Klementowicz JE, et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023;4(1):100878. doi:10.1016/j.xcrm.2022.100878.26
Rossi N, Lee KA, Bermudez MV, et al. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma. EBioMedicine. 2022;83:104235. doi:10.1016/j.ebiom.2022.104235
Palle J, Hirsch L, Lapeyre-Prost A, et al. Targeting HGF/c-met axis decreases circulating regulatory T cells accumulation in gastric cancer patients. Cancers (Basel). 2021;13(21):5562. doi:10.3390/cancers13215562
Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019;20(12):1584-1593. doi:10.1038/s41590-019-0479-x
Chen D, Tang TX, Deng H, Yang XP, Tang ZH. Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. Front Immunol. 2021;12:747324. doi:10.3389/fimmu.2021.747324
Wang C, Kong L, Kim S, et al. The role of IL-7 and IL-7R in cancer pathophysiology and immunotherapy. Int J Mol Sci. 2022;23(18):10412. doi:10.3390/ijms231810412
Kasten KR, Prakash PS, Unsinger J, et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun. 2010;78(11):4714-4722. doi:10.1128/IAI.00456-10
Jiang Q, Li W-Q, Aiello FB, Klarmann KD, Keller JR, Durum SK. Retroviral transduction of IL-7Ralpha into IL-7Ralpha−/− bone marrow progenitors: correction of lymphoid deficiency and induction of neutrophilia. Gene Ther. 2005;12(24):1761-1768. doi:10.1038/sj.gt.3302558
Schölch S, Bogner A, Bork U, et al. Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer. Sci Rep. 2019;9(1):10921. doi:10.1038/s41598-019-47429-5
Coenegrachts L, Schrauwen S, Van Bree R, et al. Increased expression of placental growth factor in high-grade endometrial carcinoma. Oncol Rep. 2013;29(2):413-418. doi:10.3892/or.2012.2178
Albonici L, Giganti MG, Modesti A, Manzari V, Bei R. Multifaceted role of the placental growth factor (PLGF) in the antitumor immune response and cancer progression. Int J Mol Sci. 2019;20(12):2970. doi:10.3390/ijms20122970
Yang Z, Chen Y, Wei X, Wu D, Min Z, Quan Y. Upregulated NTF4 in colorectal cancer promotes tumor development via regulating autophagy. Int J Oncol. 2020;56(6):1442-1454. doi:10.3892/ijo.2020.5027
Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351-357. doi:10.1001/jamaoncol.2017.4771
Takenaka Y, Oya R, Takemoto N, Inohara H. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: meta-analysis. Head Neck. 2022;44(5):1237-1245. doi:10.1002/hed.26997